Mylan works with government, trade associations, healthcare providers, patient-advocacy groups and others to shape policies that help people across the nation enjoy better health.
Mylan has a decades-long track record of expanding people’s access to medicine, particularly by making more-affordable generic versions of brand name drugs – expertise we’re now bringing to biologics, insulins and other complex medicines.
In 1984, generic drugs made up only 19% of prescriptions dispensed in the U.S.
In 2016, generic drugs made up 89% of prescriptions dispensed in the U.S., yet represent only 27% of total drug spending.
Mylan has 16 biosimilar and insulin analog products on the market around the world or in development. They include eight of the world’s top 10 biologics.
Today, 48 states have adopted such laws, and Mylan has donated more than 1 million epinephrine auto-injectors to more than 73,000 schools around the country.
of all people worldwide being treated for HIV/AIDS depend on a Mylan antiretroviral product.